







MONU YADAV, MILIND PARLE* 
Pharmacology Division, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001 
(Haryana) India 
Email: mparle@rediffmail.com     
 Received: 28 Feb 2016 Revised and Accepted: 17 May 2016 
ABSTRACT 
Objective: Pain, an unpleasant sensation that we all experience in daily life, is an alert mechanism to prevent impending tissue injury. The animal 
models employed for screening of analgesic agents include pain-state models based on the use of thermal, mechanical electrical and chemical 
stimuli. This study was undertaken with an objective to design, develop and fabricate a new animal model for screening analgesics. 
Methods: In the present study, a humble attempt is made to develop a new animal model for screening analgesics overcoming the limitations of 
earlier models. The utility of the newly developed laboratory model (M-model) of pain was compared with already established models.  
Results: A simple laboratory model for screening of analgesics was developed in the present study. In this study, endurance time was defined as the 
time for which, the animals were able to endure the cold surface of ice-floor. The animals assumed a flinching posture and fled to M-Zone when they 
were unable to withstand the cold surface. Endurance time was significantly and consistently enhanced by different classes of analgesic agents such 
as pentazocine, butorphanol, tramadol, diclofenac, ketoprofen and meloxicam. The findings obtained using M-model was in line with those obtained 
using already established models.  
Conclusion: An effective animal model for screening analgesics overcoming the limitations of earlier models was developed in this study. This 
model showed excellent face and predictive validity.  
Keywords: Pain, Analgesics, Cold stimuli, M-model, Flinching posture, Endurance time 
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INTRODUCTION 
Pain is a complex, unpleasant phenomenon composed of sensory 
and emotional experience that include time, intensity, emotion, 
cognition and motivation originating from damaged tissue [1]. It 
plays an important role as an alarm/signal that helps to protect the 
living organisms and provokes avoidance behaviour, which arrests 
the potentially damaging consequences and facilitates fundamental 
biological functions such as inflammation or healing [2]. One-third of 
the world’s population suffers from persistent or recurrent pain. 
Nociceptors are the particular sensory receptors responsible for the 
detection of noxious stimuli, transforming the stimuli into electrical 
signals, which are then conducted to the CNS [3].  
There are the free nerve endings of primary afferent Aδ and C fibres 
distributed throughout the body they can be stimulated by thermal, 
mechanical, electrical and chemical stimuli. Inflammatory mediators 
(eg. bradykinin, serotonin, prostaglandins, and cytokines) are 
released from damaged tissue and can stimulate nociceptors. They 
can also act by reducing the activation threshold of nociceptors so 
that the stimulation required to cause activation is less. In addition 
to the Aδ and C fibres that carry noxious sensory information, there 
are primary afferent Aβ fibres that bring non-noxious stimuli. These 
fibres possess different characteristics that allow the transmission of 
particular types of sensory information. Aβ fibres are highly 
myelinated and of large diameter, therefore allowing fast signal 
conduction. They have a low activation threshold and generally 
respond to light touch and transmit nonnoxious stimuli [4]. They 
respond to mechanical and thermal stimuli. C fibres are 
unmyelinated and are also the smallest type of primary afferent 
fibre. Hence, they allow the slowest conduction. C fibres respond to 
chemical, thermal and mechanical stimuli. Cold stimuli are that 
tactile sensibility and motor function deteriorate while pain 
perception persists. Nociception are the neural processes of 
encoding and processing noxious stimuli. Pain in response to a non-
nociceptive stimulus is known as allodynia and increased pain 
sensitivity is hyperalgesia. Chronic pain is associated with 
conditions such as back injury, migraine headaches, arthritis, 
diabetic neuropathy, and cancer. Many of the currently available 
pain therapies cause uncomfortable to deleterious side effects 
because of lack of perfect animal models for screening of different 
types of analgesics. Animal models serve as indispensable tools for 
discovering new medicines as well as for the analysis of the 
magnitude of causes, biomarkers, and pathophysiological changes, 
which bring about symptoms analogous to those of patients with a 
specific disorder. Since human life is precious, it becomes necessary 
to test new medicines in small animals before applying to human 
beings. Animal models provide an opportunity to decipher the 
relationships between the nervous system and animal behaviours as 
they serve as obligatory tools for screening of new drugs [5]. Pain 
cannot be monitored directly in animals, but can only be measured 
by examining their responses to nociceptive stimuli [6]. Noxious 
stimulus is often used in animal models to damage a specific tissue 
partially in order to produce pain or inflammation. The observed 
reactions are almost always motor responses ranging from spinal 
reflexes to complex behaviour.  
Animal models serve as indispensable tools for discovering 
medicines useful in the treatment of human diseases. Tail-flick 
technique and hot-plate test are commonly used for screening 
analgesic agents, although both of these models use heat as the 
noxious stimulus. At present, there are several tests in literature, 
which employ cold stimulus for studying nociception in animal’s viz. 
Paw or tail withdrawal after immersion in cold water [7, 8] or water-
alcohol bath [9], ethyl chloride spray [10], direct application of cold 
acetone [11] or contact with a Peltier the mode [12].  
However, most of these methods impose limitations on the testing 
conditions [13]. New laboratory models are difficult to develop 
particularly in the area of neuropharmacology, because of the 
complexity of the human neuronal network. Since the brain of 
animals is not so well developed as compared to human brain, it 
becomes a tough task to produce neurological disorders in 
laboratory animals. An ideal laboratory model for screening 
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analgesics agents should be able to evoke behavioral changes in 
animals, which can be quantified. These behavioral changes 
observed in animals should be reversible by the same analgesic 
agents, which are effective in human beings. In the light of the fact 
that pain is very frequently experienced by human beings in several 
disease states; there arises an urgent need to develop a suitable 
animal model for detecting different types of new analgesic agents. 
The present study was undertaken with an objective of designing, 
developing and fabrication of a simple laboratory model for 
screening of analgesic agents. 
MATERIALS AND METHODS 
Experimental animals 
A total of 138 Swiss albino mice of either sex divided into 23 groups 
were employed in the present study. Each group consisted of a 
minimum of 6 animals. Adult (3-4 mo old) mice weighing around 20-
25g were procured from the Disease-Free Small Animal House, Lala 
Lajpat Rai University of Veterinary and Animal Sciences (LUVAS) 
Hisar, Haryana (INDIA). The animals were acclimatized for at least 7 
d to the laboratory conditions before behavioral experiments. 
Animals were housed under standard conditions of temperature 
(24±2 °C) and relative humidity (30-70%) with a 12:12 light: dark 
cycle. Experiments were carried out between 09:00 h-17:00 h. The 
experimental protocol was approved by Institutional Animal Ethics 
Committee (IAEC) as per guidelines of CPCSEA, Ministry of Forests 
and Environment, Government of India (Registration number 0436).  
Induction and measurement of pain  
A New Animal Model was designed and developed in the present 
study, for induction and measurement of pain in mice. This 
laboratory model (M-model) comprised of basically four 
components i) perspex-box ii) M-Zone iii) ice-tray and iv) ice-floor. 
Initially, the mouse was exposed to various parts of the M-model 
particularly M-Zone for around 60 sec, so that the mouse was aware 
of the presence of M-Zone before the start of the experiment. The 
animal was inserted from the top/ceiling of the perspex box. The ice-
tray consisting of ice-block was slid onto the floor of the perspex 
box. The animal fled to M-Zone when it was not able to withstand or 
endure the cold surface of ice-floor. Endurance time was defined as 
the time taken by the animal to flee into the M-Zone (Flight-Zone) 
when placed on the ice-floor. Endurance time was recorded with the 
help of a stopwatch. Normally, mice take around 4-6 sec. to flee into 
the M-Zone to avoid ice-floor. The ice trays were changed for each 
group of mice so as to expose each mouse to a fresh ice-block. 
Separate groups of animals were pretreated with narcotics such as 
pentazocine (10 mg/kg, s. c), butorphanol (partial opioid agonist, 2 
mg/kg, s. c), tramadol (opioid agonist, 5 mg/kg, s. c) and non-
narcotic analgesics such as diclofenac (non-selective COX inhibitor, 
15 mg. kg, i. p), ketoprofen (non-selective COX inhibitor, 5 mg/kg, p. 
o) & meloxicam (preferential COX-2 inhibitor, 5 mg/kg, s. c) to 
determine their effect on Endurance-time. The endurance time was 
recorded at 0, 15, 30, 45, 60, 120, and 180 min after administration 
of the standard drugs.  
Experimental design  
The drugs and chemicals used in the study were procured from drug 
houses as given in the bracket. Diclofenac sodium (Voveran, 
Novartis, Mumbai), meloxicam (Meloxicam, Intas Pharmaceutical 
Ltd., Ahmadabad), Pentazocine lactate (Fortwin, Ranbaxy 
Laboratory Ltd., Ahmadabad), tramadol (Tramazac, Cadila, 
Ahmedabad), butorphanol tartrate (Butrum, Arito Pharmaceutical 
Pvt. Ltd., M. P.) and ketoprofen (Neon Laboratory Ltd Mumbai, 
India). Standard drugs such as diclofenac, meloxicam, pentazocine, 
tramadol, and butorphanol were diluted in distilled water, and 
ketoprofen was suspended in 2% of tween-80 solution. 
Groups using hot-plate test 
Group I: Control group: Distilled water was administered 
subcutaneously. The analgesic activity was recorded at 30 min after 
the administration of the Vehicle.  
Groups II, III, IV and V: Test groups: Diclofenac (15 mg/kg, i. p), 
meloxicam (5 mg/kg, s. c), pentazocine (10 mg/kg, s. c) and 
tramadol (5 mg/kg, s. c) were administered to different groups. The 
analgesic activity was recorded at 30 min after the administration of 
these drugs.  
Groups using tail-immersion test 
Group VI: Control group: Distilled water was administered 
subcutaneously. The analgesic activity was recorded at 30 min after 
the administration of the vehicle.  
Groups VII, VIII, IX and X: Test groups: Diclofenac (15 mg/kg, i. p), 
meloxicam (5 mg/kg, s. c), pentazocine (10 mg/kg, s. c) and 
tramadol (5 mg/kg, s. c) were administered to different groups. The 
analgesic activity was recorded at 30 min after the administration of 
these drugs. 
Groups for tail-flick technique  
Group XI: Control group: Distilled water was administered 
subcutaneously. The analgesic activity was recorded at 30 min after 
the administration of the vehicle.  
Groups XII, XIII, XIV and XV: Test groups: Diclofenac (15 mg/kg, i. p), 
meloxicam (5 mg/kg, s. c), pentazocine (10 mg/kg, s. c) and 
tramadol (5 mg/kg, s. c) were administered to different groups. The 
analgesic activity was recorded at 30 min after the administration of 
these drugs.  
Groups for designing and fabrication of a New, laboratory model  
Group XVI: Control group: Distilled water was administered 
subcutaneously. The analgesic activity was recorded at 30 min after 
the administration of the vehicle.  
Group XVII: Control group: tween-80 (2%) was administered per 
oral with the help of an oral needle. The analgesic activity was 
recorded at 30 min after the administration of the vehicle.  
Groups XVIII, XIX, XX, XXI, XXII and XXIII: Test groups: Diclofenac 
(15 mg/kg, i. p), ketoprofen (5 mg/kg, p. o), meloxicam (5 mg/kg, s. 
c), pentazocine (10 mg/kg, s. c), tramadol (5 mg/kg, s. c) and 
butorphanol (2 mg/kg, s. c) were administered to different groups. 
The analgesic activity was recorded at 30 min after the 
administration of these drugs. The established models such as hot-
plate test, tail-immersion test, and tail-flick technique were 
employed for comparing the utility of the newly developed model 
using narcotic (pentazocine, tramadol) and non-narcotic agents 
(diclofenac, meloxicam).  
Statistical analyses  
All the results were expressed as a Mean+Standard error of mean (S. 
E. M). Data were analyzed using one-way ANOVA followed by 
Dunnett’s test. P<0.01 was considered as statistically significant. 
RESULTS 
Description of newly developed laboratory model  
A New animal model was designed and developed in the present 
study, for inducing and measuring the pain of mice. We have named 
this newly developed model as M-model, since the shape of the M-
Zone (Flight-Zone) is like letter “M” and the first letter of the most 
powerful analgesic agent morphine is also “M”.  
Functions of various parts of the device are described below 
i) Perspex-box: Perspex-box (36 x 18 x 18 cm3
ii) M-Zone: The animal flees to M-Zone (Flight-Zone), which is 
situated at a height of 12 cm from the ice-floor, when, it is not able to 
withstand or endure the cold surface of ice-floor, which has been 
portrayed in fig. 1. The arms (18 x 3 x 3 x 18 cm
) consists of three 
transparent walls made up of Perspex so that animal behavior can 
be easily observed. The fourth wall of the box is made up of 
aluminum sheet for accommodating “M” shaped Flight-Zone. 
4
iii) Ice-tray: Ice-tray made up of aluminum sheet is fitted at the 
base of the perspex box. It comprises of ice-block to provide cold 
) of M-Zone provide 
safe and comfortable grip to the animal.  
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surface. This cold surface forms the ice-floor for the animals. The 
purpose of ice-floor is to induce mild pain in mice.  
iv) Ice-floor: Ice-floor comprised of ice spread over aluminum 
sheet to provide a cold surface. 
 
 
Fig. 1: Showing various components of the model 
 
Endpoint  
Endurance time is defined as the time for which, the animals were 
able to endure the cold surface of ice-floor. Under the influence of 
analgesics, the animals were able to withstand cold surface of ice-
floor for a longer period. The animals assume a flinching posture and 
flee to M-Zone when they are unable to withstand the cold surface.  
Flinching posture comprised of following components (fig. 2)  
i) Straightening of the tail ii) Recoiling (Shrinking) of the body  
iii) Licking of the paws iv) Ready to jump 
Induction and measurement of pain in mice using M-model  
Initially, the mouse was exposed to various parts of the M-model 
particularly M-Zone and base of the perspex box for around 60 sec, 
so that the mouse was aware of the presence of M-Zone before the 
start of the experiment. The ice-tray consisting of ice-block was slid 
onto the floor of the perspex box. The animal fled to M-Zone when it 
was not able to withstand or endure the cold surface of ice-floor. 
Normally, mice take around 4-6 sec. to flee into the M-Zone to avoid 
ice-floor. This Endurance time was significantly increased (beyond 
12 sec.) under the influence of an analgesic agent. A camera may also 
be fitted at the ceiling of the box for video recording of the behavior 
of the mouse. Separate groups of animals were pretreated with 
narcotics such as pentazocine (10 mg/kg, s. c), butorphanol (partial 
opioid agonist, 2 mg/kg, s. c), tramadol (opioid agonist, 5 mg/kg, s. c) 
and non-narcotic analgesics such as diclofenac (non-selective COX 
inhibitor, 15 mg. kg, i. p), ketoprofen (non-selective COX inhibitor, 5 
mg/kg, p. o) & meloxicam (preferential COX-2 inhibitor, 5 mg/kg, s. 
c) to determine their effect on Endurance–time. 
 
 
Fig. 2: Showing flinching posture of mouse on ice-floor 
 
The endurance time was recorded at 0, 15, 30, 45, 60, 120, and 180 
min after administration of the standard drugs. Endurance time was 
significantly (p<0.01) and consistently enhanced by different classes 
of analgesic agents such as pentazocine, butorphanol, tramadol, 
diclofenac, ketoprofen and meloxicam at 30, 45, and 60 minute time 
interval. This enhancement of endurance latency reflects the anti-
nociceptive effect of various analgesics, which has been depicted in 
fig. 3 and 4. 
 
 
Fig. 3: Effect of various narcotic agents on M-model 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, pentazocine (10 mg/kg, s. c), 
tramadol (5 mg/kg, s. c) and butorphanol (2 mg/kg, s. c) were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as 
compared to control group 
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Fig. 4: Effect of various non-narcotic agents on M-model 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, diclofenac (15 mg/kg, i. p), meloxicam (5 
mg/kg, s. c), were dissolved in distilled water (vehicle) and administered acutely to mice. “a” denotes P<0.01 as compared to control group 
 
Comparison of Newly developed model (M-model) with 
established models such as hot-plate model, tail-immersion test 
and tail-flick technique  
The utility of Newly developed laboratory model (M-model) of 
pain was compared with already established standard models 
viz. hot-plate model, tail-immersion test and tail-flick technique 
using different classes of analgesic agents such as pentazocine 
(10 mg kg-1, s. c), tramadol (5 mg kg-1, s. c), diclofenac (15 mg kg-
1, i. p) & meloxicam (5 mg kg-1
  
, s. c). The findings obtained using 
M-model were in line with those obtained using already 
established models such as hot-plate model (fig. 5 and fig. 8), 
tail-immersion test (fig. 6 and fig. 9) and tail-flick technique (fig. 
7 and fig. 10). 
 
Fig. 5: Comparison of M-model with hot-plate model using narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, pentazocine (10 mg/kg, s. c) and 
tramadol (5 mg/kg, s. c) were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as compared to control group 
 
 
Fig. 6: Comparison of M-model with tail-immersion test using narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, pentazocine (10 mg/kg, s. c) 
and tramadol (5 mg/kg, s. c) were dissolved in distilled water (vehicle) and administered acutely to mice. “a” denotes P<0.01 as compared 
to control group. 
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Fig. 7: Comparison of M-model with tail-flick technique using narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, pentazocine (10 mg/kg, s. c) and 
tramadol (5 mg/kg, s. c) were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as compared to control group 
 
 
Fig. 8: Comparison of M-model with hot-plate model using non-narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, diclofenac (15 mg/kg, i. p) and 
meloxicam (5 mg/kg, s. c), were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as compared to control group  
 
 
Fig. 9: Comparison of M-model with tail-immersion test using non-narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, diclofenac (15 mg/kg, i. p) and 
meloxicam (5 mg/kg, s. c), were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as compared to control group 
 
DISCUSSION  
Tail-flick technique and hot-plate test are commonly used for 
screening analgesic agents, although both of these models use heat 
as the noxious stimulus. Furthermore, these models are not sensitive 
enough to detect non-narcotic analgesics. At present, there are several 
tests in literature, which employ cold stimulus for studying nociception 
in animals viz. paw or tail withdrawal after immersion in cold water and 
water-alcohol bath, ethyl chloride spray, direct application of cold 
acetone and contact with a Peltier the mode [14-17].  
However, most of these tests have limitations on the testing 
conditions. For instance, immersion tests or Peltier devices require 
the animals to be restrained/ anesthetized. Acetone application or 
ethyl chloride spray produced an olfactory or auditory stimulus; 
both of these can lead to conditioned responses. Moreover, the 
stimulated area in many of these tests is possible to vary from one 
trial to the other, an important consideration given that specific area 
of the paw are differently sensitive to nociceptive stimuli. Bennett 
and Xie (1988) first used a 4 °C cold plate on a limited scale with the 
CCI model one month post-surgery. The authors quantified 
Parle et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 156-162 
 
161 
nociceptive behavior by monitoring the duration of paw lifts, a 
scoring method adopted by; however, this scoring method was 
found to be unreliable and produce variability in results [18, 19]. 
Moreover, there exists a possibility wherein; animals climb on the 
ridge of cold plate to avoid cool temperature, thereby interfering in 
the recording of withdrawal time. Hama and Sagen (1993) used 
same parameters of cold plate testing as Bennett and Xie (1988), 
with the exception that scoring took into account the number of 
contralateral responses. Thus, there was gross inconsistency in 
recording the end point. In the present study, a new laboratory 
model for screening of analgesic agents was designed, developed 
and fabricated to overcome this inconsistency using Ice-floor to 
provide cold stimulus. Although there is no agreement in the 
literature as to when cold begins to be nociceptive, temperatures 
from-12 °C to 20 °C have been investigated for their nociceptive 
ability in both humans [20] and rats. 
 
 
Fig. 10: Comparison of M-model with tail-flick technique using non-narcotic agents 
 
Values are expressed as mean±SEM (n=6). Data was analyzed by one-way ANOVA followed by Dunnett’s t-test, diclofenac (15 mg/kg, i. p) and 
meloxicam (5 mg/kg, s. c), were dissolved in distilled water (vehicle) and administered to mice. “a” denotes P<0.01 as compared to control group 
 
Essentially, the perception of a cold stimulus for inducing 
nociceptive behaviour depends on considerably upon the testing 
conditions, such as duration of the stimulus, continuous exposure, 
skin temperatures, location of the stimulated area and medium of 
stimulation (solid, liquid and gaseous). There is also sufficient 
evidence to indicate that threshold temperatures for inducing 
discomfort are slightly higher in humans, usually around 10 °C, than 
in animals at around 5 °C. This discrepancy in thresholds is likely 
due to the fact that humans can verbally express discomfort before 
the urge to withdraw is felt. In rats, the actual withdrawal response 
is likely to be triggered by recruitment of a greater number of cold 
nociceptive afferents than those needed strictly for the awareness of 
cold nociceptive stimulus. The latency to withdrawal becomes 
shorter as the testing temperature is reduced. Primary afferent Aδ 
and C fibres distributed throughout the body they can be stimulated 
by thermal stimuli such as heat or cold. In the present study, ice-
block was used to provide cold stimuli for producing mild 
pain/discomfort in mice (peculiar nociceptive behaviour), which 
was easily quantified. This observation is in agreement with the 
study of Jasmine el at., (1998) and Bennett and Xie (1988), who 
employed a cold plate for studying nociceptive behaviours in 
neuropathic injury and inflammatory pain models.  
The functioning of M-model is based on the fact that the mice flee to 
M-Zone, when they are not able to withstand or endure the cold 
surface of ice-floor. Endurance time was defined as the time taken by 
the animal to flee into the M-Zone (Flight-Zone) when placed on the 
ice-floor. Under the influence of analgesics, the animals are able to 
endure cold surface of ice-floor for a longer period. The animals 
assumed a flinching posture, just before fleeing to M-Zone, when 
they were unable to endure the cold surface. We had named this 
newly developed model as M-model, since the shape of the Flight-
Zone is like letter “M” and the first letter of the most powerful 
analgesic agent Morphine is also “M”. An ideal animal model should 
meet the fundamental criteria of good face validity, predictive 
validity and construct validity [21]. In the newly developed model 
(M-model), the pain was produced in mice by using ice-floor. The 
Ice-floor provides cold stimulus evoking mild pain sensation in mice 
equivalent to human pain experience. Animals as well as humans, 
when confronted with a physical threat exhibit behaviours that 
enable them to escape from the source of danger. This fact imparts 
excellent face validity to M-model. The animals assumed a flinching 
posture in the present study, just before fleeing to M-Zone, when 
they were unable to endure the cold surface. This typical behavioral 
response was delayed by different classes of therapeutic regimens 
effective in pain. Different categories of analgesic agents used such 
as, pentazocine, butorphanol, tramadol, diclofenac, ketoprofen & 
meloxicam successfully enhanced the endurance time of mice in the 
present study. Whereas, the vehicle did not have any significant 
effect on the endurance time. This observation confers good 
predictive validity to the M-model. The theoretical rationale 
underlying the animal model of pain and human pain experience 
contributes to the construct validity of the model. In the present 
study, the physical causes of pain, as well as the biological factors 
underlying the pain, appear to be similar in animals and human 
beings. Therefore, the construct validity of the M-model appears to 
be fairly good. Furthermore, the new model represents a very simple 
and cost-effective method for screening of analgesic agents. This 
model has immense practical and commercial applications [22].  
The efficacy of the newly developed model was compared in the 
present study with the established models such as hot-plate test, 
tail-immersion test and tail-flick technique. It is noteworthy that M-
model was at least as effective as the previous models. The newly 
developed model permits a fixed temperature setting and provides 
freedom to the animal allowing observation of spontaneous 
behaviors. This is a very simple & cost effective model. No special 
skill is required in handling of this device. Fleeing movement, 
flinching posture and endurance time observed in this model can be 
easily recorded and quantified. There was consistency while 
observing these nociceptive behaviours. There are no noxious 
stimuli such as electric shock/intense heat to the animals in this 
model. M-model developed in the present study was effective in 
detecting the analgesic activity of currently, marketed Narcotic 
analgesics such as pentazocine, butorphanol (partial-opioid agonist) 
tramadol (opioid agonist) and non-narcotic analgesics such as 
diclofenac (nonselective COX inhibitor), ketoprofen (nonselective 
COX inhibitor) & meloxicam (preferential COX-2 inhibitor). Ice-floor 
of the M-model produces mild unpleasant sensory experience 
(nociception), which is similar to pain experience of human beings. 
There is no need to anesthetize the animals or surgical procedure 
during the experiment. Thus, new substances possessing analgesic 
potential can be screened effectively using the newly developed 
model designed in this study.  
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An effective animal model for screening analgesics overcoming the 
limitations of earlier models was developed in this study. The 
findings obtained using M-model was in line with those obtained 
using already established models. This model showed excellent face 
and predictive validity.  
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